Life Technologies, the Translational Genomics Research Institute, and US Oncology said last week that they are collaborating to sequence 14 breast cancer tumors using Life Tech's SOLiD system in order to help with treatment decisions.
The samples are from patients with triple-negative breast cancer whose tumors have progressed despite other therapies. The goal of the study is "to demonstrate whether genomic sequencing of cancer tissues can provide clues for treatment strategies for these individuals," according to the partners.
Under the collaboration, US Oncology, an oncology services company based in The Woodlands, Texas, will help enroll patients in the study, who will have both their tumor and healthy tissues sequenced on the SOLiD system. Mutations identified in the study will then be validated by Caris Life Sciences, which is CLIA-certified.
Scientists and oncologists plan to use the mutational data "to more intelligently evaluate potential therapies that target the affected pathways responsible for the cancer," according to the partners.
In addition, scientists from Phoenix, Ariz.-based TGen and Life Tech plan to jointly develop new software, "paving the way" for the use of whole-genome sequencing data to query, identify, and interpret mutations in order to make more effective therapeutic decisions.